TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06683027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonattachment for Post Traumatic Stress
Description: This study seeks to cultivate nonattachment specifically for the alleviation of symptoms of post-traumatic stress. This is an 8-week online intervention where, following a Qualrics-hosted pre-screen, users are directed to www.npts.online to use as they wish. Users are then solicited to re-take quantitative assessments, and a subset of 10 (target number) will be recruited for a qualitative interview regarding their experience of the intervention.~A final prompt for assessment re-takes will follow at 3 months post-intervention to determine longitudinal efficacy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nonattachment for Post Traumatic Stress
Description: This study seeks to cultivate nonattachment specifically for the alleviation of symptoms of post-traumatic stress. This is an 8-week online intervention where, following a Qualrics-hosted pre-screen, users are directed to www.npts.online to use as they wish. Users are then solicited to re-take quantitative assessments, and a subset of 10 (target number) will be recruited for a qualitative interview regarding their experience of the intervention.~A final prompt for assessment re-takes will follow at 3 months post-intervention to determine longitudinal efficacy.
Study: NCT06683326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROKOKO smart-glove
Description: ESD expert hands and fingers motion broadcasted by the ROKOKO smart-glove to trainees
Study: NCT06683989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: The program consisted of Pilates exercises on the reformer for 40 minutes.
Study: NCT06684782

Intervention type: OTHER
Intervention: Screening for symptoms of restless leg syndrome
Description: The patients will be screened for restless leg syndrome by clinical questioning.
Study: NCT06682897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: 60 minutes each session, three sessions per week, lasting 4 weeks for undertaking.
Study: NCT06682104

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual intensive short term psychodynamic therapy
Description: ISTDP aims to help patients explore and process unconscious emotions, particularly those linked to past trauma or unresolved conflicts, that may be contributing to their physical symptoms. Patients are guided to identify and express repressed feelings such as anger, grief, or fear. The therapist actively engages the patient in a focused and intensive manner, helping them to recognize emotional defenses, break through resistance, and experience these emotions directly in the therapeutic setting.
Study: NCT06682390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric anti-inflammatory diet
Description: The anti-inflammatory hypocaloric diet combines the exclusion of pro- inflammatory constituents and inclusion of anti-inflammatory nutrients. Excluded food items will be refined carbohydrates, soda and alcoholic beverages, ultra- processed foods, smoked foods, fatty foods, packaged foods, canned products, preservatives, emulsifiers, and sauces. Reduce or eliminate red/processed meats. Included food items will be a defined minimum diversity of fruits, vegetables, and nuts based on complementary phytonutrient contents, particularly those rich in phenolic compounds such as ellagitannins and sulforaphanes. Selected herbs (e.g., turmeric, ginger, garlic, black pepper, rosemary, cardamon, cinnamon), green tea, fermented foods, fats (e.g., avocado), and oils (e.g., olive oil) will be encouraged. The goal is to have 5 servings of vegetables, 2 fruits per day, and 5 vegetable color groups per week. Participants will also be asked to reduce their kcal by 500/day and walk for 1 gr 3x per week.
Study: NCT06684990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POC testing
Description: POC testing for HbA1c and cystatin C
Study: NCT05659225

Intervention type: DEVICE
Group type: OTHER
Intervention: Electronic Stethoscope
Description: Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the electronic stethoscope group will be instructed to install the electronic stethoscope developed by our team and its accessories, then they will be trained by investigators on how to use the electronic stethoscope.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment according to GINA(2019)
Description: Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the control group will receieve standard treatment according to GINA(2019).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment according to GINA(2019)
Description: Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the control group and the electronic stethoscope group and complete their future onsite visits (V2-V5) at Shanghai Children's Medical Center. The patient's caregiver who was assigned to the control group will receieve standard treatment according to GINA(2019).
Study: NCT05794633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The patients will be recieved two days a week for 8 sessions with sterile 25\*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other.~Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks
Study: NCT04604665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High frequency postural change
Description: Repositioning of patients hospitalized in bed in intensive care units will be carried out with a frequency interval that we call high-frequency to be performed on each patient between an interval between less than or equal to every 2 hours in a full day (24 hours) (minimum goal of 8-10 in 24 hours subtracting 2 or 4 at night and not alter the circadian cycle). The position must be modified in each postural change to right lateral, supine, left lateral, or prone to supine if the position changes every 2 hrs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Repositioning of patients hospitalized will be performed in the current way it is commonly applied to patients.
Study: NCT06379009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: 12 week home-based training program
Study: NCT06683911

Intervention type: DRUG
Intervention: non Opioids
Description: It is planned to avoid opioid side effects by applying opioid-free anesthesia during the perioperative period.

Intervention type: DRUG
Intervention: Opioid
Description: Routine general anesthesia in cardiac surgery
Study: NCT04639102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PATH Intervention
Description: Patients will receive an enhanced level of care and service:~1. Discharge planning- PATH clinicians will develop an individualized treatment plan at time of ED discharge. Each patient will receive next-day phone call to monitor status. There will be additional patient and family education, triage of new or worsening symptoms, and additional telephone contact as determined in treatment plan. There will be communication with home health teams as needed.~2. Care coordination- PATH clinicians will arrange necessary primary medical doctor and specialty appointments. They will also communicate treatment plan to outpatient provider and arrange transportation for patients.~3. Home monitoring/ Home Health Services- If patients are eligible and consent to home health services, they will be enrolled in Penn Medicine Home Health (PMHH). This will include virtual home monitoring, skilled nurse care, home physical and occupational therapists, social work services, and wound care.
Study: NCT06341855

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRD-ctDNA
Description: ctDNA-MRD is a powerful biomarker, and ctDNA-MRD is a reliable predictive biomarker in EC.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRD-ctDNA
Description: ctDNA-MRD is a powerful biomarker, and ctDNA-MRD is a reliable predictive biomarker in EC.
Study: NCT06155812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of vasopressors
Description: Early, simultaneous administration of norepinephrine, angiotensin II, and vasopressin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Successive administration of vasopressors
Description: Administration and titration of norepinephrine and administration of additional vasoactive drugs (epinephrine, methylene blue, angiotensin II, dobutamine, or dopamine) as per clinical team.
Study: NCT06336655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IABP
Description: LV unloading via intra-aortic balloon pump (IABP)
Study: NCT05206955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 10 mg once daily orally week 1, 20 mg once daily orally during week 2, and 40 mg once daily orally during weeks 3 through 52
Study: NCT05365243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMMA Portalbe Scalp Cooling System
Description: AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center and at home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
Study: NCT05206955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Looks exactly like the study drug, but it contains no active ingredient
Study: NCT04691986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside is a form of vitamin B3 and is naturally occurring in humans.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills contain micro cellulose powder.
Study: NCT04767555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ILM (inner limiting membrane) peeling
Description: The standard technique for the removal of the inner limiting membrane is a dye-assisted ILM peeling established since 20 years as the standard of care to treat vision loss due to epiretinal membranes or macular holes in eyes with an otherwise stable retina, but not during retinal detachment surgery. Other dyes may show a stronger staining effect but since there is evidence of a potential toxicity of ICG the investigators use the well-tolerated and for this purpose approved trypan blue dye Membrane Blue ® (Dorc). This intervention will be performed in addition to standard vitreoretinal re-attachment surgery.
Study: NCT05245149

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac CTA on a photon-counting detector CT (PCD-CT)
Description: Cardiac CTA will be performed on a dual-source photon-counting CT

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac CTA on a regular CT with Energy-Integrating Detector (EID-CT)
Description: Cardiac CTA was performed on a dual-source CT with regular energy-integrating detector (EID-CT)
Study: NCT06348030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Signia Stapler
Description: The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vessel Sealer Extend Energy Device and SureForm Stapler
Description: The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
Study: NCT04229095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant 20 mg
Description: Single-dose administration of 20 mg suvorexant given on an inpatient clinical research unit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Single-dose administration of placebo given on an inpatient clinical research unit
Study: NCT05460923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: including trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss Ball Exercises
Description: trunk twists, supine to sit, knee to chest, crawling, and bridges. Every session will be 45 minutes. Patients will be given 5 sessions per week and the study will last for 12 months
Study: NCT04848584

Intervention type: BIOLOGICAL
Intervention: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
Description: prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study

Intervention type: BIOLOGICAL
Intervention: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
Description: prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study

Intervention type: BIOLOGICAL
Intervention: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
Description: prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study

Intervention type: BIOLOGICAL
Intervention: Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
Description: prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study

Intervention type: BIOLOGICAL
Intervention: BNT162b2 BA.4/5 bivalent
Description: Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.

Intervention type: BIOLOGICAL
Intervention: BNT162b2 BA.4/5 bivalent
Description: Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.

Intervention type: BIOLOGICAL
Intervention: BNT162b2 BA.4/5 bivalent
Description: Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.

Intervention type: BIOLOGICAL
Intervention: BNT162b2 BA.4/5 bivalent
Description: Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.

Intervention type: BIOLOGICAL
Intervention: XBB.1.5-adapted vaccinated
Description: Vaccinated with XBB.1.5-adapted vaccine

Intervention type: BIOLOGICAL
Intervention: XBB.1.5-adapted vaccinated
Description: Vaccinated with XBB.1.5-adapted vaccine
Study: NCT06128733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent Meningococcal ABCYW vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalent Meningococcal ABCYW vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACYW conjugate vaccine
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group B vaccine
Description: Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group B vaccine
Description: Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal group B vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACYW conjugate vaccine
Description: Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACYW conjugate vaccine
Description: Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenABCYW conjugate vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
Study: NCT06026657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Naxitamab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor Expanded TGF-beta-imprinted NK Cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor Expanded TGF-beta-imprinted NK Cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor Expanded TGF-beta-imprinted NK Cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor Expanded TGF-beta-imprinted NK Cells
Description: Given IV
Study: NCT06298461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KleanLyte
Description: Laxative for colonoscopy bowel preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bi-PegLyte
Description: Laxative for colonoscopy bowel preparation
Study: NCT06301555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement learning algorithm powered cognitive and behavioral intervention
Description: Reinforcement learning algorithm powered cognitive and behavioral intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive and behavioral intervention
Description: cognitive and behavioral intervention
Study: NCT06244303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)
Description: Toothpaste, toothbrush \& mouthwash regime
Study: NCT06192615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine
Description: Intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg)
Study: NCT06244303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)
Description: Toothpaste, toothbrush \& mouthwash regime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: manual toothbrush + Colgate dental cream
Description: toothpaste + toothbrush

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: manual toothbrush + Colgate dental cream
Description: toothpaste + toothbrush